Literature DB >> 22410756

[Sleep-disordered breathing and cardiac resynchronization therapy].

A-M Sinha1.   

Abstract

Patients with progressive heart failure often suffer from sleep-disordered breathing (SDB). Upon receiving cardiac resynchronization therapy (CRT), there is an improvement of cardiac function and central sleep apnea syndrome (CSA) with Cheyne-Stokes respiration; however, effects of CRT on obstructive sleep apnea syndrome seemed to be without clinical relevance. Likewise, additional atrial overdrive pacing did not improve CRT effects relevantly in CSA patients. During CRT, there is an improvement in sleep parameters, sleep quality by reduction of depressive syndromes, and in long-term survival. Therefore, all patients with chronic heart failure and indication for CRT should be monitored regarding SDB before and after CRT device implantation.

Entities:  

Mesh:

Year:  2012        PMID: 22410756     DOI: 10.1007/s00399-012-0168-z

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  28 in total

Review 1.  Sleep apnea and heart failure: Part II: central sleep apnea.

Authors:  T Douglas Bradley; John S Floras
Journal:  Circulation       Date:  2003-04-08       Impact factor: 29.690

2.  2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association.

Authors:  Kenneth Dickstein; Panos E Vardas; Angelo Auricchio; Jean-Claude Daubert; Cecilia Linde; John McMurray; Piotr Ponikowski; Silvia Giuliana Priori; Richard Sutton; Dirk J van Veldhuisen
Journal:  Eur Heart J       Date:  2010-08-27       Impact factor: 29.983

3.  Influence of cardiac resynchronisation therapy on different types of sleep disordered breathing.

Authors:  Olaf Oldenburg; Lothar Faber; Jürgen Vogt; Anja Dorszewski; Florian Szabados; Dieter Horstkotte; Barbara Lamp
Journal:  Eur J Heart Fail       Date:  2007-04-27       Impact factor: 15.534

4.  Improvement in Cheyne-Stokes respiration following cardiac resynchronisation therapy.

Authors:  J Y Gabor; D A Newman; V Barnard-Roberts; V Korley; I Mangat; P Dorian; P J Hanly
Journal:  Eur Respir J       Date:  2005-07       Impact factor: 16.671

5.  A mechanism of central sleep apnea in patients with heart failure.

Authors:  S Javaheri
Journal:  N Engl J Med       Date:  1999-09-23       Impact factor: 91.245

6.  Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure.

Authors:  P A Lanfranchi; A Braghiroli; E Bosimini; G Mazzuero; R Colombo; C F Donner; P Giannuzzi
Journal:  Circulation       Date:  1999-03-23       Impact factor: 29.690

7.  Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.

Authors:  Jose M Marin; Santiago J Carrizo; Eugenio Vicente; Alvar G N Agusti
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 8.  Sleep-related breathing disorders and cardiovascular disease.

Authors:  F Roux; C D'Ambrosio; V Mohsenin
Journal:  Am J Med       Date:  2000-04-01       Impact factor: 4.965

9.  Enhanced ventilatory response to exercise in patients with chronic heart failure and central sleep apnea.

Authors:  Michael Arzt; Martina Harth; Andreas Luchner; Frank Muders; Stephan R Holmer; Friedrich C Blumberg; Günter A J Riegger; Michael Pfeifer
Journal:  Circulation       Date:  2003-04-14       Impact factor: 29.690

10.  Periodic breathing during incremental exercise predicts mortality in patients with chronic heart failure evaluated for cardiac transplantation.

Authors:  Joao J Leite; Alfredo J Mansur; Humberto F G de Freitas; Paulo R Chizola; Edimar A Bocchi; Mario Terra-Filho; J Alberto Neder; Geraldo Lorenzi-Filho
Journal:  J Am Coll Cardiol       Date:  2003-06-18       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.